Multiple Myeloma and Plasma Cell Disorders: Update On Diagnosis, Prognosis, Treatment, and Supportive Care
This supplement to JADPRO has been developed by members of the International Myeloma Foundation (IMF) Nurse Leadership Board.
Log in or Sign up at www.advancedpractitioner.com
CE Credits valid through July 1, 2024
IMF NLB Board Members Beth Faiman, PhD, MSN, APRN-BC, AOCN, BMTCN, FAAN (Cleveland Clinic Taussig Cancer Institute—Cleveland, OH) and Tiffany Richards, PhD, ANP-BC, AOCNP (The University of Texas MD Anderson Cancer Center—Houston, TX) are guest editors of the publication.
“Advances in the diagnosis and management of multiple myeloma (MM) and other plasma cell disorders such as AL amyloidosis and Waldenström macroglobulinemia (WM) continue to evolve rapidly. Over the past several years, there have been significant gains in understanding disease biology, leading to improvements in diagnostic techniques, a shift towards targeted therapies, and a potential transition away from traditional chemotherapeutic agents as the standard of care.”
This CE-certified supplement provides FREE Credits/Contact Hours for Nurses and other Advanced Practitioners; it is jointly provided by the IMF, the Annenberg Center for Health Sciences at Eisenhower, and JADPRO.
Supported by educational grants from:
AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Biotech, administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics, Legend Biotech, Oncopeptides, Sanofi Genzyme, and Takeda Pharmaceuticals